Neil Senzer

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

Robert H.I. Andtbacka, Howard L. Kaufman, Frances A. Collichio et al. · Journal of Clinical Oncology · 2015 · 2.6K citations · Full text

Medicine, Immunology, Oncology +17

Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

Denis Soulières, Neil Senzer, Everett E. Vokes et al. · Journal of Clinical Oncology · 2003 · 808 citations · Full text

Medicine, Oncology, Pharmacology +11

Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma

Neil Senzer, Howard L. Kaufman, Thomas Amatruda et al. · Journal of Clinical Oncology · 2009 · 615 citations · Full text

Medicine, Clinical Sciences, Oncology +17

Phase II Study of Belagenpumatucel-L, a Transforming Growth Factor Beta-2 Antisense Gene-Modified Allogeneic Tumor Cell Vaccine in Non–Small-Cell Lung Cancer

John Nemunaitis, Robert O. Dillman, Paul Schwarzenberger et al. · Journal of Clinical Oncology · 2006 · 359 citations · Full text

Medicine, Immunology, Oncology +17

Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients

John Nemunaitis, Casey Cunningham, Neil Senzer et al. · Cancer Gene Therapy · 2003 · 338 citations

Medicine, Biotechnology, Oncology +9